This move is archived. Current quotes and coverage live on the stock page.
Follow BLCO
Bausch + Lomb Corp is experiencing a notable rise in its stock price, reflecting positive investor sentiment driven by recent developments.
Bausch + Lomb Corp (BLCO.TO) shares increased by 3.67% in the last trading session, closing at CA$24.32. This uptick follows new survey data showing how much dry eye treatments can improve patients' quality of life, potentially strengthening the company's position in the eye health sector.
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$10.29B
52W high
$29.73
52W low
$20.25
1W change
+0.74%
Beta
0.52
Analyst Price Targets
Based on analyst covering BLCO · as of Nov 6, 2026
Wall Street analysts forecast BLCO stock price to fall 5.6% over the next 12 months.
Consensus
Moderately BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$26.38
-5.6% Upside
Previously C$26.31 on Nov 5, 2026
Current Price
C$27.96
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
55.3%
Annualized
90-Day Vol
39.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$33.43
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$29.67 | C$24.52 – C$35.91 |
| 60 trading days | C$31.49 | C$24.04 – C$41.25 |
| 90 trading days | C$33.43 | C$24.02 – C$46.52 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should consider the implications of Bausch + Lomb's recent survey findings, which could boost demand for their dry eye products and positively affect future sales.
3.67% Increase in Stock Price
Bausch + Lomb's stock price rise reflects positive investor sentiment following new data on the benefits of dry eye treatments.
Bull case
The recent survey results show that treating dry eye symptoms can significantly enhance patients' emotional well-being and self-confidence. This suggests a growing market for Bausch + Lomb's products.
Bear case
Despite the encouraging survey data, the company still faces challenges, including a negative profit margin and the ongoing need for innovation to maintain a competitive edge in the healthcare market.
Survey Findings Boost Investor Confidence
The latest survey conducted by Bausch + Lomb indicates that a significant majority of dry eye sufferers see improvements in their quality of life after treatment. These findings highlight the importance of effective dry eye management and could lead to increased demand for the company's products, positively impacting future sales.
Market Position and Future Outlook
With a market cap of over CA$8.5 billion, Bausch + Lomb is well-positioned in the eye health industry. However, investors should remain cautious, as the company still deals with a negative profit margin and must continue innovating to stay ahead of competitors in a rapidly changing market.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
